A liaison between mTOR signaling, ribosome biogenesis and cancer

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 7, 2015, Pages 812-820

  Gentilella, Antonio ^a   Kozma, Sara C ^a,b   Thomas, George ^a,b  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; MTOR; Ribosomal protein; Ribosome biogenesis

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

BIOGENESIS; CARCINOGENESIS; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RIBOSOME; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

EUKARYOTA; PROKARYOTA;

ANIMALS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BIOSYNTHESIS; RIBOSOMES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84930818367     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2015.02.005     Document Type: Review

References (126)

1. Beldade P., Mateus A.R., Keller R.A. Evolution and molecular mechanisms of adaptive developmental plasticity. Mol. Ecol. 2011, 20:1347-1363.
2. Woolford J.L., Baserga S.J. Ribosome biogenesis in the yeast Saccharomyces cerevisiae. Genetics 2013, 195:643-681.
3. Noeske J., Cate J.H. Structural basis for protein synthesis: snapshots of the ribosome in motion. Curr. Opin. Struct. Biol. 2012, 22:743-749.
4. van Riggelen J., Yetil A., Felsher D.W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 2010, 10:301-309.
5. Lempiainen H., Shore D. Growth control and ribosome biogenesis. Curr. Opin. Cell Biol. 2009, 21:855-863.
6. Granneman S., Baserga S.J. Ribosome biogenesis: of knobs and RNA processing. Exp. Cell Res. 2004, 296:43-50.
7. Mayer C., Grummt I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 2006, 25:6384-6391.
8. Tschochner H., Hurt E. Pre-ribosomes on the road from the nucleolus to the cytoplasm. Trends Cell Biol. 2003, 13:255-263.
9. Ciganda M., Williams N. Eukaryotic 5S rRNA biogenesis. Wiley Interdiscip. Rev. RNA 2011, 2:523-533.
10. Hu H., Li X. Transcriptional regulation in eukaryotic ribosomal protein genes. Genomics 2007, 90:421-423.
11. Zemp I., Kutay U. Nuclear export and cytoplasmic maturation of ribosomal subunits. FEBS Lett. 2007, 581:2783-2793.
12. Teng T., Mercer C.A., Hexley P., Thomas G., Fumagalli S. Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. Mol. Cell. Biol. 2013, 33:4660-4671.
13. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 2004, 10:484-486.
14. Rosen N., She Q.B. AKT and cancer-is it all mTOR?. Cancer Cell 2006, 10:254-256.
15. Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010, 1:530-543.
16. Ferreira-Cerca S., Hurt E. Cell biology: arrest by ribosome. Nature 2009, 459:46-47.
17. Teng T., Thomas G., Mercer C.A. Growth control and ribosomopathies. Curr. Opin. Genet. Dev. 2013, 23:63-71.
18. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253:905-909.
19. Kunz J., Henriquez R., Schneider U., Deuter-Reinhard M., Movva N.R., Hall M.N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993, 73:585-596.
20. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78:35-43.
21. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
22. Chiu M.I., Katz H., Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12574-12578.
23. Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Weiderrecht G., Abraham R.T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 1995, 270:815-822.
24. Brunn G.J., Hudson C.C., Sekulic A., Williams J.M., Hosoi H., Houghton P.J., Lawrence J.C., Abraham R.T. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997, 277:99-101.
25. Burnett P.E., Barrow R.K., Cohen N., Snyder S.H., Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1432-1437.
26. Plas D.R., Thomas G. Tubers and tumors: rapamycin therapy for benign and malignant tumors. Curr. Opin. Cell Biol. 2009.
27. Kim D.H., Sarbassov dos D., Ali S.M., Latek R.R., Guntur K.V., Erdjument-Bromage H., Tempst P., Sabatini D.M. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 2003, 11:895-904.
28. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
29. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
30. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
31. Zheng X.-F., Florentino D., Chen J., Crabtree G.R., Schreiber S.L. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 1995, 82:121-130.
32. Oldham S., Montagne J., Radimerski T., Thomas G., Hafen E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 2000, 14:2689-2694.
33. Gangloff Y.G., Mueller M., Dann S.G., Svoboda P., Sticker M., Spetz J.F., Um S.H., Brown E.J., Cereghini S., Thomas G., Kozma S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 2004, 24:9508-9516.
34. Murakami M., Ichisaka T., Maeda M., Oshiro N., Hara K., Edenhofer F., Kiyama H., Yonezawa K., Yamanaka S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 2004, 24:6710-6718.
35. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11:859-871.
36. Pende M., Kozma S.C., Jaquet M., Oorschot V., Burcelin R., Le Marchand-Brustel Y., Klumperman J., Thorens B., Thomas G. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 2000, 408:994-997.
37. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
38. Pende M., Um S.H., Mieulet V., Sticker M., Goss V.L., Mestan J., Mueller M., Fumagalli S., Kozma S.C., Thomas G. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 2004, 24:3112-3124.
39. Le Bacquer O., Petroulakis E., Paglialunga S., Poulin F., Richard D., Cianflone K., Sonenberg N. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin. Invest. 2007, 117:387-396.
40. Tsukiyama-Kohara K., Poulin F., Kohara M., DeMaria C.T., Cheng A., Wu Z., Gingras A.C., Katsume A., Elchebly M., Spiegelman B.M., Harper M.E., Tremblay M.L., Sonenberg N. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat. Med. 2001, 7:1128-1132.
41. Carnevalli L.S., Masuda K., Frigerio F., Le Bacquer O., Um S.H., Gandin V., Topisirovic I., Sonenberg N., Thomas G., Kozma S.C. S6K1 plays a critical role in early adipocyte differentiation. Dev. Cell 2010, 18:763-774.
42. Chuang J.H., Tung L.C., Yin Y., Lin Y. Differentiation of glutamatergic neurons from mouse embryonic stem cells requires raptor S6K signaling. Stem Cell Res. 2013, 11:1117-1128.
43. Yang L., Miao L., Liang F., Huang H., Teng X., Li S., Nuriddinov J., Selzer M.E., Hu Y. The mTORC1 effectors S6K1 and 4E-BP play different roles in CNS axon regeneration. Nat. Commun. 2014, 5:5416.
44. Antion M.D., Merhav M., Hoeffer C.A., Reis G., Kozma S.C., Thomas G., Schuman E.M., Rosenblum K., Klann E. Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. Learn. Mem. 2008, 15:29-38.
45. Hartman N.W., Lin T.V., Zhang L., Paquelet G.E., Feliciano D.M., Bordey A. mTORC1 targets the translational repressor 4E-BP2, but not S6 kinase 1/2, to regulate neural stem cell self-renewal in vivo. Cell Rep. 2013, 5:433-444.
46. Gkogkas C.G., Sonenberg N. Translational control and autism-like behaviors. Cell Logist. 2013, 3:e24551.
47. Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C., Hemmings B.A., Thomas G. Phosphorylation and activation of p70s6k by PDK1. Science 1998, 279:707-710.
48. Biondi R.M., Kieloch A., Currie R.A., Deak M., Alessi D.R. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 2001, 20:4380-4390.
49. Holz M.K., Ballif B.A., Gygi S.P., Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005, 123:569-580.
50. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731-745.
51. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., Sabatini D.M. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
52. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314:467-471.
53. Wang X., Li W., Williams M., Terada N., Alessi D.R., Proud C.G. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J. 2001, 20:4370-4379.
54. Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013, 339:1323-1328.
55. Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 2013, 339:1320-1323.
56. Lane A.N., Fan T.W. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015, 43(4):2466-2485.
57. Mayer C., Zhao J., Yuan X., Grummt I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev. 2004, 18:423-434.
58. Hannan K.M., Brandenburger Y., Jenkins A., Sharkey K., Cavanaugh A., Rothblum L., Moss T., Poortinga G., McArthur G.A., Pearson R.B., Hannan R.D. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 2003, 23:8862-8877.
59. Chauvin C., Koka V., Nouschi A., Mieulet V., Hoareau-Aveilla C., Dreazen A., Cagnard N., Carpentier W., Kiss T., Meyuhas O., Pende M. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 2014, 33(4):474-483.
60. Pause A., Belsham G.J., Gingras A.-C., Donzé O., Lin T.A., Lawrence J.C., Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 1994, 371:762-767.
61. Gingras A.-C., Kennedy S.G., O'Leary M.A., Sonenberg N., Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and activated by the Akt (PKB) signaling pathway. Genes Dev. 1998, 12:502-513.
62. Gingras A.C., Gygi S.P., Raught B., Polakiewicz R.D., Abraham R.T., Hoekstra M.F., Aebersold R., Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999, 13:1422-1437.
63. Gingras A.C., Raught B., Gygi S.P., Niedzwiecka A., Miron M., Burley S.K., Polakiewicz R.D., Wyslouch-Cieszynska A., Aebersold R., Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001, 15:2852-2864.
64. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
65. Dowling R.J., Topisirovic I., Alain T., Bidinosti M., Fonseca B.D., Petroulakis E., Wang X., Larsson O., Selvaraj A., Liu Y., Kozma S.C., Thomas G., Sonenberg N. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010, 328:1172-1176.
66. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., Natt F., Hall J., Lane H.A., Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
67. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17414-17419.
68. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. J. Biol. Chem. 2009, 284(12):8023-8032.
69. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
70. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., Shi E.Y., Stumpf C.R., Christensen C., Bonham M.J., Wang S., Ren P., Martin M., Jessen K., Feldman M.E., Weissman J.S., Shokat K.M., Rommel C., Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
71. Levy S., Avni D., Hariharan N., Perry R.P., Meyuhas O. Oligopyrimidine tract at the 5' end of mammalian ribosomal protein mRNAs is required for their translational control. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3319-3323.
72. Jefferies H.B., Reinhard C., Kozma S.C., Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4441-4445.
73. Jefferies H.B., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997, 16:3693-3704.
74. Thoreen C.C., Chantranupong L., Keys H.R., Wang T., Gray N.S., Sabatini D.M. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012, 485:109-113.
75. Shor B., Wu J., Shakey Q., Toral-Barza L., Shi C., Follettie M., Yu K. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J. Biol. Chem. 2010, 285:15380-15392.
76. Kantidakis T., Ramsbottom B.A., Birch J.L., Dowding S.N., White R.J. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11823-11828.
77. Zinzalla V., Stracka D., Oppliger W., Hall M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144:757-768.
78. Chan J.C., Hannan K.M., Riddell K., Ng P.Y., Peck A., Lee R.S., Hung S., Astle M.V., Bywater M., Wall M., Poortinga G., Jastrzebski K., Sheppard K.E., Hemmings B.A., Hall M.N., Johnstone R.W., McArthur G.A., Hannan R.D., Pearson R.B. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci. Signal. 2011, 4:ra56.
79. Avni D., Shama S., Loreni F., Meyuhas O. Vertebrate mRNAs with a 5'-terminal pyrimidine tract are candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element. Mol. Cell. Biol. 1994, 14:3822-3833.
80. Ruvinsky I., Sharon N., Lerer T., Cohen H., Stolovich-Rain M., Nir T., Dor Y., Zisman P., Meyuhas O. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 2005, 19:2199-2211.
81. Gentilella A., Thomas G. Cancer biology: the director's cut. Nature 2012, 485:50-51.
82. Shama S., Avni D., Frederickson R.M., Sonenberg N., Meyuhas O. Overexpression of initiation factor eIF-4E does not relieve the translational repression of ribosomal protein mRNAs in quiescent cells. Gene Expr. 1995, 4:241-252.
83. Damgaard C.K., Lykke-Andersen J. Translational coregulation of 5'TOP mRNAs by TIA-1 and TIAR. Genes Dev. 2011, 25:2057-2068.
84. Orom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 2008, 30:460-471.
85. Ivanov P., Kedersha N., Anderson P. Stress puts TIA on TOP. Genes Dev. 2011, 25:2119-2124.
86. Patursky-Polischuk I., Kasir J., Miloslavski R., Hayouka Z., Hausner-Hanochi M., Stolovich-Rain M., Tsukerman P., Biton M., Mudhasani R., Jones S.N., Meyuhas O. Reassessment of the role of TSC, mTORC1 and microRNAs in amino acids-meditated translational control of TOP mRNAs. PLoS One 2014, 9:e109410.
87. Yu Y., Yoon S.O., Poulogiannis G., Yang Q., Ma X.M., Villen J., Kubica N., Hoffman G.R., Cantley L.C., Gygi S.P., Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
88. Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
89. Aoki K., Adachi S., Homoto M., Kusano H., Koike K., Natsume T. LARP1 specifically recognizes the 3' terminus of poly(A) mRNA. FEBS Lett. 2013, 587:2173-2178.
90. Tcherkezian J., Cargnello M., Romeo Y., Huttlin E.L., Lavoie G., Gygi S.P., Roux P.P. Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation. Genes Dev. 2014, 28:357-371.
91. Dibble C.C., Elis W., Menon S., Qin W., Klekota J., Asara J.M., Finan P.M., Kwiatkowski D.J., Murphy L.O., Manning B.D. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol. Cell 2012, 47:535-546.
92. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N. Engl. J. Med. 2006, 355:1345-1356.
93. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37:217-222.
94. Dienstmann R., Rodon J., Serra V., Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer Ther. 2014, 13:1021-1031.
95. Abraham J. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?. Expert Rev. Anticancer Ther. 2015, 15:51-68.
96. Pagliarini R., Shao W., Sellers W.R. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 2015, 16(3):280-296.
97. Mura M., Hopkins T.G., Michael T., Abd-Latip N., Weir J., Aboagye E., Mauri F., Jameson C., Sturge J., Gabra H., Bushell M., Willis A.E., Curry E., Blagden S.P. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene 2014, [Epub ahead of print].
98. Xie C., Huang L., Xie S., Xie D., Zhang G., Wang P., Peng L., Gao Z. LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. J. Transl. Med. 2013, 11:272.
99. Barna M., Pusic A., Zollo O., Costa M., Kondrashov N., Rego E., Rao P.H., Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008, 456:971-975.
100. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2009, 17:249-261.
101. Pourdehnad M., Truitt M.L., Siddiqi I.N., Ducker G.S., Shokat K.M., Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:11988-11993.
102. Volarevic S., Stewart M.J., Ledermann B., Zilberman F., Terracciano L., Montini E., Grompe M., Kozma S.C., Thomas G. Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science 2000, 288:2045-2047.
103. Fumagalli S., Di Cara A., Neb-Gulati A., Natt F., Schwemberger S., Hall J., Babcock G.F., Bernardi R., Pandolfi P.P., Thomas G. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 2009, 11:501-508.
104. Panic L., Tamarut S., Sticker-Jantscheff M., Barkic M., Solter D., Uzelac M., Grabusic K., Volarevic S. Ribosomal protein S6 gene haploinsufficiency is associated with activation of a p53-dependent checkpoint during gastrulation. Mol. Cell. Biol. 2006, 26:8880-8891.
105. Barkic M., Crnomarkovic S., Grabusic K., Bogetic I., Panic L., Tamarut S., Cokaric M., Jeric I., Vidak S., Volarevic S. The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival. Mol. Cell. Biol. 2009, 29:2489-2504.
106. Macias E., Jin A., Deisenroth C., Bhat K., Mao H., Lindstrom M.S., Zhang Y. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 2010, 18:231-243.
107. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16:369-377.
108. Fumagalli S., Thomas G. The role of p53 in ribosomopathies. Semin. Hematol. 2011, 48:97-105.
109. Teng T., Thomas G., Mercer C.A. Growth control and ribosomopathies. Curr. Opin. Genet. Dev. 2013, 23(1):63-71.
110. Pestov D.G., Strezoska Z., Lau L.F. Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. Mol. Cell. Biol. 2001, 21:4246-4255.
111. Lohrum M.A., Ludwig R.L., Kubbutat M.H., Hanlon M., Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3:577-587.
112. Sun X.X., Dai M.S., Lu H. 5-Fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 2007, 282:8052-8059.
113. Sun X.X., Dai M.S., Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J. Biol. Chem. 2008, 283:12387-12392.
114. Yuan X., Zhou Y., Casanova E., Chai M., Kiss E., Grone H.J., Schutz G., Grummt I. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol. Cell 2005, 19:77-87.
115. Fumagalli S., Ivanenkov V.V., Teng T., Thomas G. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev. 2012, 26:1028-1040.
116. Donati G., Peddigari S., Mercer C.A., Thomas G. 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep. 2013, 4:87-98.
117. Bursac S., Brdovcak M.C., Pfannkuchen M., Orsolic I., Golomb L., Zhu Y., Katz C., Daftuar L., Grabusic K., Vukelic I., Filic V., Oren M., Prives C., Volarevic S. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:20467-20472.
118. Sloan K.E., Bohnsack M.T., Watkins N.J. The 5S RNP couples p53 homeostasis to ribosome biogenesis and nucleolar stress. Cell Rep. 2013, 5(1):237-247.
119. Yadav G.V., Chakraborty A., Uechi T., Kenmochi N. Ribosomal protein deficiency causes Tp53-independent erythropoiesis failure in zebrafish. Int. J. Biochem. Cell Biol. 2014, 49:1-7.
120. Taylor A.M., Humphries J.M., White R.M., Murphey R.D., Burns C.E., Zon L.I. Hematopoietic defects in rps29 mutant zebrafish depend upon p53 activation. Exp. Hematol. 2012, 40:228-237.e225.
121. Payne E.M., Virgilio M., Narla A., Sun H., Levine M., Paw B.H., Berliner N., Look A.T., Ebert B.L., Khanna-Gupta A. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. Blood 2012, 120:2214-2224.
122. Bywater M.J., Poortinga G., Sanij E., Hein N., Peck A., Cullinane C., Wall M., Cluse L., Drygin D., Anderes K., Huser N., Proffitt C., Bliesath J., Haddach M., Schwaebe M.K., Ryckman D.M., Rice W.G., Schmitt C., Lowe S.W., Johnstone R.W., Pearson R.B., McArthur G.A., Hannan R.D. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012, 22:51-65.
123. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
124. Liu Q., Thoreen C., Wang J., Sabatini D., Gray N.S. mTOR mediated anti-cancer drug discovery. Drug Discov. Today Ther. Strateg. 2009, 6:47-55.
125. Garcia-Echeverria C. Blocking the mTOR pathway: a drug discovery perspective. Biochem. Soc. Trans. 2011, 39:451-455.
126. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.